Skip to main content
Publications
Rashid S, Januwalla A, Moore J, Park J, Rup J, Khan A, Straus SE, Tu J, CANHEART SPOR Research Team 2. The Cardiovascular Health in Ambulatory Care Research Team (CANHEART) Initiative: using implementation science to improve dyslipidemia management in Ontario. Poster presented at the International Symposium on Atherosclerosis (ISA) 2018; June 9, 2018. Toronto, Canada. [abstract] Atherosclerosis. 2018 Jun; 32:54-5. doi: 10.1016/j.atherosclerosissup.2018.04.164
Varadhachary GR, Spector Y, Abbruzzese JL, Rosenwald S, Wang H, Aharonov R, Carlson HR, Cohen D, Karanth S, Macinskas J, Lenzi R, Chajut A, Edmonston TB, Raber MN. Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary. Clin Cancer Res. 2011 Jun 15;17(12):4063-70. doi: 10.1158/1078-0432.CCR-10-2599
Ireland H, Konstantoulas CJ, Cooper JA, Hawe E, Humphries SE, Mather H, Goodall AH, Hogwood J, Juhan-Vague I, Yudkin JS, di Minno G, Margaglione M, Hamsten A, Miller GJ, Bauer KA, Kim YT, Stearns-Kurosawa DJ, Kurosawa S. EPCR Ser219Gly: elevated sEPCR, prothrombin F1+2, risk for coronary heart disease, and increased sEPCR shedding in vitro. Atherosclerosis. 2005;183(2):283-92.
Morange PE, Saut N, Alessi MC, Frere C, Hawe E, Yudkin JS, Tremoli E, Margaglione M, di Minno G, Hamsten A, Humphries SE, Juhan-Vague I, Hifmech Study Group. HIFMECH Study Group. Interaction between the C-260T polymorphism of the CD14 gene and the plasma IL-6 concentration on the risk of myocardial infarction: the HIFMECH study. Atherosclerosis. 2005;179(2):317-23.
Elrayess MA, Webb KE, Bellingan GJ, Whittall RA, Kabir J, Hawe E, Syvänne M, Taskinen MR, Frick MH, Nieminen MS, Kesäniemi YA, Pasternack A, Miller GJ, Humphries SE. R643G polymorphism in PECAM-1 influences transendothelial migration of monocytes and is associated with progression of CHD and CHD events. Atherosclerosis. 2004;177(1):105-12.
LoRusso PM, Herbst RS, Rischin D, Ranson M, Calvert H, Raymond E, Kieback D, Kaye S, Gianni L, Harris A, Bjork T, Maddox A, Rothenberg ML, Small EJ, Rubin EH, Feyereislova A, Heyes A, Averbuch SD, Ochs J, Baselga J. Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. Clin Cancer Res. 2003 Jun 1;9(6):2040-8.